Palbociclib
- PDF / 151,437 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 1 Downloads / 158 Views
1 S
Esophagitis and gastritis: case report A 67-year-old woman developed esophagitis and gastritis during treatment with palbociclib for metastatic breast cancer. The woman was diagnosed with Stage IIA pT2N0M0 ER+/PR+/HER2- left breast intraductal carcinoma at the age of 63 years. She underwent lumpectomy followed by chemoradiation and tamoxifen. At age of 65 years, she was found to have calcifications in her right breast and had metastasis to ilium and bone. Therefore, she started receiving oral palbociclib 125mg for 21 days and letrozole. Three weeks after the initiation of palbociclib, she received palliative radiation. Four days later, she presented to an emergency room with odynophagia and dysphagia to solids and liquids, non-bilious hematemesis and dyspepsia for 5 days. Esophagogastroduodenoscopy (EGD) showed severe ulcerative esophagitis in the distal third of esophagus along with gastritis. Strictures were also noted in the distal third of the esophagus. Biopsy revealed reactive squamous mucosa inflammation along with multiple ulcerations in the esophagus, stomach, and duodenum. The woman was admitted, and palbociclib was stopped. She was treated with pantoprazole and a clear liquid diet. On day 4 of admission, she was able to tolerate a soft diet. She was restarted on letrozole and discharged home. One month later, she presented to a oncology clinic. She continued to tolerate a diet and reported significant improvement in dysphagia and odynophagia. Therefore, she restarted oral palbociclib 125mg for 21 days, without radiation treatment. Two months following the discharge, repeated EGD showed significant improvement in esophagitis and gastritis. It was reported that she developed esophagitis and gastritis due to the palbociclib and concurrent radiation therapy. Nasir UM, et al. Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy. Anticancer Research 40: 5291-5294, No. 9, Sep 2020. Available from: URL: http://doi.org/10.21873/anticanres.14534 803506601
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
